Contact | Compliance | Reimbursement | Supply Updates | Supplier Link
Investor Relations

A HERITAGE OF INNOVATION AND LEADERSHIP

Lantheus Medical Imaging, a global leader in developing, manufacturing, selling, and distributing innovative diagnostic imaging agents, is dedicated to creating and providing medical imaging solutions to improve the treatment of human disease.

Our expertise in discovering, developing and commercializing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus has a rich heritage and expertise in cardiovascular imaging and nuclear medicine, having pioneered many of the most significant products used in medical imaging.

Our current imaging agents primarily assist in the diagnosis of heart, vascular and other diseases using nuclear imaging, echocardiography and magnetic resonance imaging (MRI) technologies. We have a pipeline of next-generation and first-in-class products using Positron Emission Tomography (PET) and MRI technologies.

Our vision is to be the leading provider of innovative medical imaging solutions to improve human life. We are committed to developing next generation and first-in-class imaging agents to assist physicians in the diagnosis of heart, vascular and other diseases.

With direct operations in the United States, Puerto Rico, Canada and Australia, we have a long and distinguished history of developing and commercializing innovative market-changing products.

Recent News

LANTHEUS HOLDINGS, INC. ANNOUNCES FILING OF REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING

No. BILLERICA, Mass. (June 24, 2014) – Lantheus Holdings, Inc. (“Lantheus Holdings” or the “Company”), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. Lantheus Holdings intends to apply to list its common stock on the NASDAQ Global under the ticker symbol “LNTH.” The number of shares to be offered and the price range of the proposed offering have not yet been determined. Lantheus Holdings expects to use the net proceeds of the offering to repay indebtedness of LMI and for working capital and general corporate purposes.

click here for the press release

 

 

Company Spotlight

 

© 2014 Lantheus Medical Imaging, Inc. Contact | Compliance | Reimbursement | Supply Updates | Supplier Link | Site Map